Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
ConclusionsThese findings suggest that ETV- and TAF-treated CHB patients have similar risk of developing HCC. Further studies with the larger sample size and longer follow-up are needed to validate these results.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Academia | Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Hypertension | Infectious Diseases | Liver | Liver Cancer | Statistics | Study | Teaching | Teaching Hospitals | Universities & Medical Training | Urology & Nephrology | Viread